Spain Archives

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

22/04/2021 No Comments

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

The Chloroquine Wars Part XV – How to Rig Research: Surgisphere Part II

15/04/2021 No Comments

It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.

Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis

18/03/2021 No Comments

Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.

Ivermectin is effective for COVID-19: real-time meta analysis of 42 studies

23/02/2021 No Comments

Ivermectin is an effective treatment for COVID-19. The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

28/01/2021 No Comments

Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew

An alternative to the vaccine: an antiparasitic to reduce the transmission of COVID

27/01/2021 No Comments

Source: AS.com A study by ISGlobal and the Clínica Universidad de Navarra points to a significant reduction in viral load in those who received ivermectin.

Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

27/01/2021 No Comments

Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days

A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.

05/12/2020 No Comments

Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.

HCQ is effective for COVID-19 when used early: analysis of 132 studies

02/11/2020 No Comments

Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 132 studies to date is

Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2

26/10/2020 No Comments

We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.

Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)

15/10/2020 No Comments

The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.

Spain/US – Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19 (HCQ reduces the risk of COVID-19 by about 20%)

29/09/2020 No Comments

Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There is disagreement about whether hydroxychloroquine (HCQ) is effective as prophylaxis

Vitamin D3 mixed with hydroxychloroquine shows promise in treating COVID-19: Study

04/09/2020 No Comments

Source: Washington Examiner Author: David Hogberg A new study finds that COVID-19 patients with acute respiratory infections may improve with a regimen of Vitamin D3, hydroxychloroquine, and

Spain – 1766P COVID-19 and lung cancer: What do we know?

01/09/2020 No Comments

There seems to be a trend towards lower mortality among patients who received treatment with the combination of hydroxychloroquine and azithromycin than among those who did not

Why do Asian countries use hydroxychloroquine for Covid-19 despite Western rejection?

31/08/2020 No Comments

Asian countries overall have fared better in controlling Covid-19, with lower mortality which is due to demographics and use of HCQ.

Spanish Study -The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.

21/08/2020 No Comments

Corticosteroid treatment didn’t correlate with death in our model whereas both hydroxychloroquine and azithromycin correlated with a lower mortality rate.

Madrid Study: Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid – Risk of death significantly lower with HCQ

17/07/2020 No Comments

Source: Medrxiv.org In this analysis of 1645 patients hospitalized with COVID-19 we find that the risk of death was significantly lower for patients treated with

Spain Study: A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.

12/06/2020 No Comments

None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.

HIBISCUS: Hydroxychloroquine for the Secondary Prevention of Thrombotic and Obstetrical Events in Primary Antiphospholipid Syndrome

17/12/2018 No Comments

Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16].

The Palmer Foundation

Category: Spain